Emerald Mutual Fund Advisers Trust Reduces Position in Soleno Therapeutics, Inc. $SLNO

Emerald Mutual Fund Advisers Trust decreased its stake in shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 6.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 379,900 shares of the company’s stock after selling 25,751 shares during the quarter. Soleno Therapeutics comprises 1.3% of Emerald Mutual Fund Advisers Trust’s holdings, making the stock its 20th biggest position. Emerald Mutual Fund Advisers Trust owned approximately 0.71% of Soleno Therapeutics worth $25,681,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in SLNO. Allspring Global Investments Holdings LLC raised its stake in Soleno Therapeutics by 255.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 280,984 shares of the company’s stock worth $18,995,000 after acquiring an additional 201,983 shares during the last quarter. Castleark Management LLC purchased a new stake in Soleno Therapeutics during the 2nd quarter valued at about $2,919,000. TD Asset Management Inc increased its holdings in shares of Soleno Therapeutics by 34.9% in the second quarter. TD Asset Management Inc now owns 99,810 shares of the company’s stock valued at $8,362,000 after purchasing an additional 25,800 shares during the period. SG Americas Securities LLC purchased a new position in shares of Soleno Therapeutics in the third quarter worth about $1,000,000. Finally, Marshall Wace LLP raised its stake in shares of Soleno Therapeutics by 133.0% in the second quarter. Marshall Wace LLP now owns 288,334 shares of the company’s stock worth $24,157,000 after purchasing an additional 164,580 shares during the last quarter. Hedge funds and other institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics Stock Performance

Shares of NASDAQ SLNO opened at $43.75 on Friday. The company has a market capitalization of $2.35 billion, a PE ratio of -23.78 and a beta of -3.12. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.88 and a current ratio of 16.08. The company’s fifty day moving average price is $47.25 and its 200 day moving average price is $61.57. Soleno Therapeutics, Inc. has a 1 year low of $39.43 and a 1 year high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.39. The firm had revenue of $66.02 million during the quarter, compared to analysts’ expectations of $47.46 million. On average, research analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Key Headlines Impacting Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised EPS forecasts across 2025–2026 (Q4‑2025, Q1‑2026, full‑year 2025 and 2026 and quarterly 2026 guidance) and reiterated a “Buy” rating with a $120 price target — the firm now models FY2026 EPS of $4.82, up sharply from prior estimates, signaling an expectation of rapid revenue/profit growth that supports higher valuation. HC Wainwright raises estimates (MarketBeat)
• Positive Sentiment: Cantor Fitzgerald reiterated an Overweight rating and set a $123 price target after citing that Soleno’s Vykat has captured roughly 12.5% market share in Prader‑Willi Syndrome — market‑share gains for a specialty orphan drug are a clear revenue catalyst and justify higher forward multiples. Soleno Therapeutics Inc. (SLNO): Analysts See Major Upside
• Neutral Sentiment: Despite these upgrades, consensus estimates still show a negative EPS for the current fiscal year (consensus ~‑$3.72); analysts’ upgrades reflect rapid expected improvement but also introduce execution risk—stock performance will depend on continued uptake of Vykat and whether results match the newly raised projections. SLNO company page (MarketBeat)

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wells Fargo & Company reiterated an “overweight” rating and issued a $114.00 price target (up previously from $106.00) on shares of Soleno Therapeutics in a report on Tuesday. Wolfe Research set a $60.00 price objective on shares of Soleno Therapeutics in a research note on Monday, January 12th. HC Wainwright reissued a “buy” rating and set a $120.00 target price (up previously from $110.00) on shares of Soleno Therapeutics in a report on Tuesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a report on Wednesday, October 8th. Finally, Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research note on Tuesday, January 13th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $110.62.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.